RxDoctor Payments Data

Brett Cucchiara, MD

Vascular Neurology · Philadelphia, PANPI 1942241674

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,287 of the $2,383 with a category attached, or 96.0%. Bayer accounts for 96.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,753 and has fallen 65.2% since, to $611 in 2024.

$2,383in general payments, 2019–2025

Across 6 payments — averaging $397.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Philips North America LLC$43
  • Biogen$37
  • Medtronic$16
$1,050,874in research payments, 2019–2025

Across 32 payments — averaging $32,840 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$659K
  • Imperative Care, Inc$327K
  • Janssen Research & Development, LLC$44K
  • Novo Nordisk AS$21K

What the payments were for

  • Consulting fees$2,28796%
  • Food & beverage$964%

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer2$2,287
Philips North America LLC2$43
Biogen1$37
Medtronic1$16

How this compares

$2,383 in reported general payments places this provider in the 80th percentile of 52 vascular neurology providers in Pennsylvania.

See all vascular neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,131
Medicare patients
228
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$9,298
ClopidogrelClopidogrel Bisulfate12$419

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →